From GNYDM 2014: Learning more about PeriRx and a new salivary test for oral cancer

November 30, 2014
Kevin Henry
Issue 11

PeriRx LLC, a developer of breakthrough, non-invasive, oral diagnostic technology, recently made its national debut at the Greater New York Dental Meeting. Anastasia Turchetta, RDH, the editor of Modern Hygienist, was there to talk to Stephen M. Swanick, CEO and founder of PeriRx, LLC, about the company and what it can offer the dental community.

PeriRx LLC, a developer of breakthrough, non-invasive, oral diagnostic technology, recently made its national debut at the Greater New York Dental Meeting. Anastasia Turchetta, RDH, the editor of Modern Hygienist, was there to talk to Stephen M. Swanick, CEO and founder of PeriRx, LLC, about the company and what it can offer the dental community.

Development of this simple-to-use, painless and accurate test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles. What’s more, more than a decade of National Institute of Dental and Craniofacial Research and National Institute of Health-supported research make SaliMark™ OSCC the world’s most scientifically-validated molecular DNA biomarker test for oral squamous cell carcinoma.

For more information about PeriRx, LLC or its SaliMark OSCC salivary test for oral cancer, visit www.PeriRx.com, call (610) 544-3500, or send an email to info@PeriRx.com.

VIDEO: The link between oral sex and oral cancer

About SaliMark™ OSCC
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark™ OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.  Recently, the SaliMark™ OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University and the St. Johns Providence Health System in Detroit.

About PeriRx LLC:
Based in Broomall, Pa., PeriRx LLC is a developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.  

The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.

PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.

Free e-book: What you need to know about oral cancer detection